Alnylam Pharmaceuticals has put its dancing shoes on to raise awareness of the experience of living with acute hepatic porphyria (AHP). | Alnylam Pharmaceuticals has put its dancing shoes on to raise ...

A month after the FDA lifted its clinical hold on GSK’s vaginal yeast infection drug Brexafemme (ibrexafungerp), the ...

Novartis’ $1.7 billion Regulus Therapeutics buyout last month came after a hard-fought battle in which the Swiss pharma and ...

While the Trump administration’s threat of pharmaceutical import tariffs and most favored nation (MFN) drug pricing has ...

After a poor showing of its COVID med vilobelimab in a rare skin disorder trial, German drugmaker InflaRx is going back to ...

Following a string of vaccine expansion projects last year, Sanofi is eyeing a new path to potentially grow the reach of its ...

Just a week after the FDA updated its stance on new COVID-19 | The CDC's recommended immunization schedule no longer includes ...

AbbVie’s Allergan aesthetics unit is tightening up its workforce with 202 layoffs. | The layoffs at Allergan's Irvine, ...

As it works to send opioid use disorder (OUD) treatment Sublocade back into its prior growth territory, Indivior is switching up its commercial team. | As it works to send opioid use disorder ...

Self-regulatory body the PMCPA ruled the company brought discredit on the pharma industry by giving 21 tickets to the games, ...

After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

Despite hiring a commercial chief and sponsoring disease awareness efforts last year, Savara will have to wait a while longer ...